Stockscreener 앱 받기
8.28
7.07%
-0.63
전일 마감가:
$8.91
열려 있는:
$8.61
하루 거래량:
1.39M
Relative Volume:
1.00
시가총액:
$735.30M
수익:
$73.48M
순이익/손실:
$-108.30M
주가수익비율:
-3.68
EPS:
-2.25
순현금흐름:
$-67.17M
1주 성능:
+0.85%
1개월 성능:
-11.82%
6개월 성능:
+78.45%
1년 성능:
+52.49%
1일 변동 폭
$8.01
$8.84
1주일 범위
$8.01
$9.558
52주 변동 폭
$2.8262
$11.50
Personalis Inc Stock (PSNL) Company Profile
명칭
Personalis Inc
전화
650-752-1300
주소
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
8.28 | 791.25M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
510.93 | 193.53B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
209.50 | 149.33B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
635.66 | 50.36B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
122.90 | 35.73B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
333.33 | 32.24B | 3.17B | 642.63M | 539.81M | 10.77 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 재개 | Morgan Stanley | Equal-Weight |
| 2025-05-15 | 개시 | Guggenheim | Buy |
| 2025-03-17 | 개시 | Craig Hallum | Buy |
| 2023-02-06 | 업그레이드 | Needham | Hold → Buy |
| 2022-01-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-11-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | 다운그레이드 | Needham | Buy → Hold |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-09-20 | 재확인 | Needham | Buy |
| 2021-05-06 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-01-28 | 개시 | Truist | Buy |
| 2021-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-12 | 재확인 | Needham | Buy |
| 2020-11-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-10-19 | 개시 | Citigroup | Buy |
| 2020-10-08 | 개시 | BTIG Research | Buy |
| 2020-08-27 | 개시 | H.C. Wainwright | Buy |
| 2020-08-18 | 개시 | Needham | Buy |
| 2019-09-26 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | 개시 | BofA/Merrill | Neutral |
| 2019-07-15 | 개시 | Cowen | Outperform |
| 2019-07-15 | 개시 | Morgan Stanley | Overweight |
| 2019-07-15 | 개시 | Oppenheimer | Outperform |
모두보기
Personalis Inc 주식(PSNL)의 최신 뉴스
How Personalis Inc. stock performs in weak economyJuly 2025 Macro Moves & Entry Point Confirmation Alerts - mfd.ru
Personalis (NASDAQ:PSNL) Shares Down 4.8%Should You Sell? - MarketBeat
Aberdeen Group plc Increases Stock Position in Personalis, Inc. $PSNL - MarketBeat
Personalis (PSNL) to Release Earnings on Thursday - MarketBeat
Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference - BioSpace
Personalis (NASDAQ:PSNL) Trading Up 6.2%Time to Buy? - MarketBeat
Personalis, Inc. (PSNL) ctDNA Test Predicts TNBC Relapse Risk Post-Therapy - MSN
Why Personalis Inc. stock could benefit from AI revolutionJuly 2025 Movers & Low Risk Growth Stock Ideas - mfd.ru
Personalis gains as VA awards work order worth up to $13.5M - MSN
Personalis, Inc. (NASDAQ:PSNL) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Aug Mood: Is Personalis Inc showing insider buyingTrade Entry Report & Real-Time Price Movement Reports - baoquankhu1.vn
Personalis, Inc. (PSNL) Stock Analysis: Evaluating a 34.51% Upside Potential in the Diagnostics Sector - DirectorsTalk Interviews
Aug Patterns: Will Personalis Inc outperform small cap indexesJuly 2025 Volume & Capital Protection Trade Alerts - baoquankhu1.vn
Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Why Personalis Stock Is Rising: Medicare Covers Luncg Cancer MRD Test - MSN
Personalis Data Breach Lawsuit Investigation - Claim Depot
Medicare Now Covers NeXT Personal® MRD Testing for Lung Cancer SurveillancePersonalis, Inc. - Oncodaily
Personalis (NASDAQ:PSNL) Price Target Raised to $13.00 - MarketBeat
Will Personalis Inc. outperform small cap indexesJuly 2025 Big Picture & High Conviction Investment Ideas - mfd.ru
Medicare approves Personalis’ lung cancer test for surveillance By Investing.com - Investing.com Australia
Biotech operator Personalis sees 10% spike from Medicare covering lung cancer blood test - Mugglehead Investment Magazine
Personalis (PSNL) Gains 10% Following Medicare Coverage for Canc - GuruFocus
Medicare approves Personalis’ lung cancer test for surveillance - Investing.com Nigeria
Personalis stock rises after Medicare approves lung cancer test coverage - Investing.com South Africa
Personalis (NASDAQ:PSNL) Shares Gap UpShould You Buy? - MarketBeat
Personalis stock rises after Medicare approves lung cancer test coverage By Investing.com - Investing.com Australia
Personalis wins Medicare coverage for NeXT Personal (PSNL) - Seeking Alpha
Why Is Personalis Stock Soaring Tuesday?Personalis (NASDAQ:PSNL) - Benzinga
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test - Asianet Newsable
Personalis rises as Medicare extends coverage to lung cancer test - TradingView
Personalis Inc receives Medicare coverage for Next Personal in lung cancer surveillance - marketscreener.com
Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance - Business Wire
Personalis Inc Receives Medicare Coverage For Next Personal In Lung Cancer Surveillance - TradingView
Revenue Check: Can Personalis Inc stock double in the next yearJuly 2025 Reactions & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Wellington Shields Capital Management LLC Cuts Stake in Personalis, Inc. $PSNL - MarketBeat
Breakthrough Cancer Monitoring Technique Fuels Growth for Personalis - AD HOC NEWS
Aug Final Week: Is Personalis Inc showing insider buyingLong Setup & AI Enhanced Trading Signals - baoquankhu1.vn
Personalis, Inc. (PSNL): A Bull Case Theory - Yahoo Finance
Personalis (PSNL) Study Highlights NeXT Personal's Impact in Can - GuruFocus
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors - Business Wire
Personalis, Inc. (PSNL) Stock Analysis: A 11.76% Potential Upside Amidst Revenue Challenges - DirectorsTalk Interviews
Wall Street Zen Upgrades Personalis (NASDAQ:PSNL) to Hold - MarketBeat
Is Personalis Inc.’s growth already priced inJuly 2025 Recap & Consistent Return Strategy Ideas - mfd.ru
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference - BioSpace
Insider Selling: Personalis (NASDAQ:PSNL) CFO Sells $13,811.50 in Stock - Defense World
What 9 Analyst Ratings Have To Say About Personalis - Benzinga
Guggenheim Raises Price Target for Personalis (PSNL) to $13.00 | PSNL Stock News - GuruFocus
Personalis Inc (PSNL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.01%
0.07%
자본화:
|
볼륨(24시간):